The Board will hold a public hearing (on a date to be determined no later than February 27, 2019) to determine whether Horizon Therapeutics Canada is selling or has sold PROCYSBI (cysteamine bitartrate) in any market in Canada at a price that, in the Board's opinion, is or was excessive; and if so, what order, if any, should be made to remedy the excessive pricing.
News Release; Notice of Hearing; Statement of Allegations of Board Staff
Related Publications & Articles
-
2024 mid-year highlights in Canadian life sciences IP and regulatory law
In the first half of 2024, Rx IP Update reported on a number of developments in Canadian life sciences IP and regulatory law. The Rx IP Update team at Smart & Biggar has collected the top stories ...Read More -
Discussion Guide for PMPRB Phase 2 Consultations on New Guidelines outlines proposed new framework for patented medicine price review
This article provides an overview of the price review framework proposed by the PMPRB and key topics on which stakeholder feedback is sought.Read More -
Manitoba last province to introduce Biosimilars Initiative, while Ontario adds four drugs to its Biosimilar Policy
Manitoba has implemented a Biosimilars Initiative effective August 1, 2024.Read More